Wilmington, Delaware, United States, Transparency Market Research Inc.: Carcinoid syndrome is a combination of symptoms such as abnormal laboratory finding and physical manifestation.
Wilmington, Delaware, United States, Transparency Market Research Inc.: Carcinoid syndrome is a combination of symptoms such as abnormal laboratory finding and physical manifestation. It is most commonly seen in patients with carcinoid tumor. Diarrhea, tachycardia, bronchospasm, shortness of breathing, and flushing are most common symptoms of carcinoid syndrome.
Read Report Overview - https://www.transparencymarketresearch.com/carcinoid-syndrome-diarrhea-treatment-market.html
Carcinoid crisis during surgery and carcinoid heart diseases are the complications associated with the carcinoid syndrome
Carcinoid syndrome diarrhea involves the presence of excess serotonin, which stimulates secretion of colonic mucus, increases the peristalsis, and inhibits absorption in the GI tract which leads to diarrhea
Key Drivers, Restraints and Opportunities of Carcinoid Syndrome Diarrhea Treatment Market
- Increase in prevalence of carcinoid syndrome is anticipated to drive the carcinoid syndrome diarrhea treatment market. For instance, according to an article published in Clinics, estimated 60% to 80% prevalence of carcinoid syndrome associated diarrhea has been observed among neuroendocrine tumor patients with elevated urinary 5 – HIAA.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75165
- According to an article published in Biomedical Journal of Scientific & Technical Research (BJSTR), diarrhea accounts for 80% of carcinoid syndrome
- Currently used therapies for carcinoid syndrome are systemic chemotherapy, tyrosin kinase inhibitors, somatostatin analogues, interferon, and systemic chemotherapy. Introduction of new therapies by key industry players for the treatment of carcinoid syndrome diarrhea is likely to fuel the growth of carcinoid syndrome diarrhea treatment market.
- For instance, in October 2018, Ipsen Biopharmaceuticals Canada Inc. received approval for XERMELOTM from Health Canada
- In February 2018, Health Canada approved Somatuline Autogel for the treatment of carcinoid syndrome offered by Ipsen Biopharmaceuticals Canada Inc.
- In February 2017, Food and Drug Administration approved Xermelo (telotristat ethyl) with combination of somatostatin analog (SSA) therapy for the treatment of carcinoid syndrome diarrhea in adult patients
- Increase in awareness about life-threatening complications of carcinoid syndrome is likely to propel the growth of market. For instance, according to an article published in Neoplasia, NETs (neuroendocrine tumors) accounted for 0.5% of all diagnosed malignancies and the rise in incidence of NETs due to improved awareness is approximately 5.86 per 100,000 population per year.
- Rise in number of people with carcinoid syndrome in developing countries offers significant opportunities in carcinoid syndrome diarrhea treatment
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=75165
North America to Hold Major Share of Global Carcinoid Syndrome Diarrhea Treatment Market
- North America is expected to hold major share of the global carcinoid syndrome diarrhea treatment market, owing to rise in prevalence of carcinoid syndrome. As per an article published in the Multidisciplinary Digital Publishing Institute, in the U.S., 20% to 30% patients with NET are diagnosed with carcinoid syndrome. According to an article published in Oncotarget, the prevalence of neuroendocrine tumor is high but relatively low incidence. In the U.S., incidence of NETs has risen 6-fold over the last few decades.
- The carcinoid syndrome diarrhea treatment market in Europe is expected to hold significant share of the market. According to the NHS, in the U.K., approximately 2,900 people are diagnosed with neuroendocrine tumor each year. In July 2017, Ipsen Biopharmaceuticals, Inc. received positive opinion for Xermelo from Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA). This is a positive milestone in providing innovative solution for treatment of neuroendocrine tumors.
Make an Enquiry before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=75165
Key Players Operating in Global Carcinoid Syndrome Diarrhea Treatment Market
The global carcinoid syndrome diarrhea treatment market is highly concentrated due to the presence of key players. A large number of manufacturers hold a major share in their respective region. Key developments such as product launch and approval is by industry players are likely to fuel the growth of the market. For instance, in September 2017, Ipsen Biopharmaceuticals, Inc. received approval from European Commission for Xermelo for the treatment of carcinoid syndrome diarrhea.
Leading players operating in the global carcinoid syndrome diarrhea treatment market are:
- Novartis Pharmaceuticals Corporation
- LEXICON PHARMACEUTICALS, INC
- Ipsen Biopharmaceuticals, Inc.
More Trending Reports by Transparency Market Research –
Anthelmintic Drugs Market: the anthelmintic drugs market was valued at ~US$ 2 Bn in 2019 and is anticipated to expand at a CAGR of ~5% from 2020 to 2030.
Life Care Solution Services Market: The life care solution services market is anticipated to cross a value of US$ 2.7 Bn by 2031. Factors such as technological advancements in healthcare solutions and services.
Mercury Poisoning Treatment Market: The mercury poisoning treatment market for mercury poisoning treatment is projected to expand at a favorable CAGR of ~5% during the forecast period.
Addiction Treatment Market: The global addiction treatment market is expected to attain a market value of ~US$ 12 Bn by the of 2030.
Human Papillomavirus and Cytomegalovirus Therapeutics Market: Companies in the human papillomavirus and cytomegalovirus therapeutics market are becoming increasingly aware about one dose of HPV vaccine, which is relatively more effective than multiple doses.
Hydrocortisone Market: Adrenocortical insufficiency is one of the key medical indications that demand hydrocortisone drugs and the market is predicted to reach a value of ~US$ 2 Bn by the end of 2028.
Multiple Sclerosis Drugs Market: The global multiple sclerosis drugs market, which was valued at US$ 20 Bn in 2019, is expected to reach US$ 31.5 Bn by 2027.
Cholesterol Lowering Drugs Market: Increase in prevalence of coronary artery disease due to the formation of bad cholesterol is a major factor responsible for the global cholesterol lowering drugs market growth.
About Us
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com